-
Chenji Wang/Yao Li's team revealed the oncogenic mechanism by which SPOP gene mutations promote
Time of Update: 2023-02-03
Fig. 1: SPOP-mediated BRAF ubiquitination modification to regulate the pattern of MAPK-ERK signaling pathwayFeng Kai, a master's student in the School of Life Sciences (currently a doctoral student at the Institute of Phenotypic Group), and Qing Shi, a postdoctoral student, are co-first authors of the paper.
-
The new computer program "learns" to identify mosaic mutations that cause disease
Time of Update: 2023-02-03
Video: In this scientific demonstration, researchers at the University of California, San Diego describe using machine learning to train artificial neural networks to spot tiny mutations in genetic sequences better and faster than the human eye.
-
Science, which can fight against persistent virus mutations!
Time of Update: 2023-02-02
Referrals, live broadcasts/events01/12 14:00-16:00 OnlineOlink Multiomics Cohort ForumScan the code to participate for free03/02-03 09:00-18:00 ShanghaiThe 2nd Yangtze River Delta Single-cell Omics Technology Application ForumScan the code to participate for freeThis article is the original of Translational Medicine Network, please indicate the source for reprintingWritten by JevinSummary: The new coronavirus SARS-CoV-2 continues to accumulate mutations, and the immune escape ability is getting stronger and stronger, resulting in breakthrough infections that people still have after vaccination.
-
An article combing: Exploration of immunotherapy resistance mechanism and antimicrotherapy strategy of advanced NSCLC without driver gene mutation
Time of Update: 2023-02-02
In a follow-up phase II study, the investigators are exploring the efficacy of JTX-4014, a novel PD-1 monoclonal antibody, ± vopratelimab, in patients with high ICOS expression, EGFR wild-type, platinum-containing therapy progression, and no immunotherapy NSCLC.
-
No fear of virus mutation: Lanke/Xu Ke's team proposed a new strategy for the design of a broad-spectrum vaccine for the new crown
Time of Update: 2023-02-02
The epidemic caused by the novel coronavirus (SARS-CoV-2) is still ongoing, and so far the number of new coronavirus infections worldwide has reached more than 640 million, and more than 6. 6 million
-
Takeda's lung cancer drug has been approved for marketing in China for only one rare mutation, but some patients really need it
Time of Update: 2023-02-01
The world's first oral targeted drug "Mobosetinib" for the treatment of EGFR exon 20 exon 20 with mutation in advanced non-small cell lung cancer was approved in China!
-
Research Grant: How Mutations Help Pancreatic Cancer Grow
Time of Update: 2023-02-01
Patra has studied a number of genetic abnormalities associated with pancreatic cancer, including a gene called GNAS.
Patra said he is very excited about the future of the project and believes that the environment of the cancer center, UC School of Medicine and the research community is key to his success.
-
, Chinese Academy of Sciences, found that XBB acquired a new mutation with low cell lethality that was less toxic than other Omicron mutant strains
Time of Update: 2023-02-01
The toxicity of the T11A mutant envelope protein was significantly reducedBased on the above results, the researchers believe that the pathogenicity of the XBB strain will be further weakened compared with the previous Omicron subvariant.
-
Why older fathers pass on more genetic mutations to their offspring?
Time of Update: 2023-02-01
”essayTranscriptional and mutational signatures of the Drosophila ageing germline RNA sequencing data from Drosophila testicles showed significant differences between older sperm-associated cells (blue-green on the left) and younger sperm-associated cells (pink on the right).
-
Aging: Studying combinations of genetic mutations may hold promise to uncover specific biomarkers of Alzheimer's disease in humans
Time of Update: 2023-02-01
Associations of the APOE ε2 and ε4 alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer's disease biomarkers, Aging (2022).
Associations of the APOE ε2 and ε4 alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer's disease biomarkers, Aging (2022).
-
Clinical application of BRAF V600 mutation frequency and its inhibitors in glioma patients
Time of Update: 2023-02-01
In 93 studies on BRAFi, data were collected on 394 patients, including 241 children, 144 adults, and 9 NR.
In 93 studies on BRAFi, data were collected on 394 patients, including 241 children, 144 adults, and 9 NR.
-
Nature: Mitochondria have a waste disposal mechanism that gets rid of mutated mtDNA
Time of Update: 2023-01-06
"essayMitochondrial membrane proteins and VPS35 orchestrate selective removal of mtDNA Scientists at the University of Cologne have discovered how cells eliminate mutated mitochondrial DNA (mtDNA).
"essayMitochondrial membrane proteins and VPS35 orchestrate selective removal of mtDNA Scientists at the University of Cologne have discovered how cells eliminate mutated mitochondrial DNA (mtDNA).
-
Nature: Mitochondria have a waste disposal mechanism that gets rid of mutated mtDNA
Time of Update: 2023-01-06
"essayMitochondrial membrane proteins and VPS35 orchestrate selective removal of mtDNA Scientists at the University of Cologne have discovered how cells eliminate mutated mitochondrial DNA (mtDNA).
"essayMitochondrial membrane proteins and VPS35 orchestrate selective removal of mtDNA Scientists at the University of Cologne have discovered how cells eliminate mutated mitochondrial DNA (mtDNA).
-
Science Bulletin CCIN mutations cause teratospermia and male infertility
Time of Update: 2023-01-06
CCIN mutation leading to sperm head malformation and male infertilityStarting from clinical male infertility cases, this study identifies new pathogenic gene mutations and elucidates the relevant mechanisms through basic research, and explores corresponding treatment strategies, providing important clues for genetic counseling and assisted reproduction treatment in clinical male infertility cases.
-
Efficacy of Midostaurin in combination with intensive chemotherapy in young and elderly patients with AML with FLT3-ITD mutations
Time of Update: 2023-01-06
In a randomized Phase 3 pivotal CALGB 10603 (RATIFY) trial comparing placebo, patients aged 18 to 59 years with newly diagnosed AML with FLT3 mutation experienced significant improvements in overall survival (OS) and event-free survival (EFS) after receiving midostaurin plus intensive chemotherapy sequential 1-year midostaurin maintenance therapy.